GRIA1 and acute lymphoblastic leukemia: Given the importance and frequency of the occurrence of AEs due to the use of L-Asp in patients with ALL and the fact that there are no studies of this type in the Mexican population, our study aims to identify individual patient characteristics and risk associations of the SNVs GRIA1 rs4958351, rs6889909, and NFATC2 rs60211 on the development of L-Asp-related adverse events, such as hypersensitivity reactions and pancreatitis, in children with ALL undergoing treatment.